Global Primary Hepatocytes Market
Global Primary Hepatocytes Market

Primary Hepatocytes Comprehensive Study by Type (Human Primary Cells, Animal Primary Cells), End-Use Industry (Hospitals, Clinic Centre, Pharmaceuticals, Research institutes, Diagnostics laboratories) Players and Region - Global Market Outlook to 2026

Primary Hepatocytes Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 219 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Primary Hepatocytes Market Overview:
Primary hepatocytes are the human origin, used in conditions like malignancies and their management and new drug innovations, screening of drugs, monocloning of antibodies.

Growth Drivers
  • Development of therapeutic antibodies for the treatment of diseases
  • Rising demand for biotechnology and pharmaceutical industry


Opportunities
  • Technological advancement in the healthcare industry

Challenges
  • An increasing number of diseases


Competitive Landscape:
Companies in the market are concentrating on nephron genetic testing. North America, growing healthcare expenditure, an increasing number of chronic diseases, growing geriatric population.
Some of the key players profiled in the report are Thermo Fisher Scientific, Inc. (United States), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (United States), PromoCell GmbH (Germany), HemaCare Corporation (United States), ZenBio, Inc. (United States), STEMCELL Technologies, Inc. (Canada), Axol Bioscience Ltd. (United Kingdom), iXCells Biotechnologies (United States), BioIVT (United States) and ScienCell Research Laboratories, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like BPS Bioscience, Inc. (California), ReachBio LLC (United States) and Biopredic International (France). Analyst at AMA Research see United States Players to retain maximum share of Global Primary Hepatocytes market by 2026. Considering Market by Type, the sub-segment i.e. Human Primary Cells will boost the Primary Hepatocytes market. Considering Market by End-Use Industry, the sub-segment i.e. Hospitals will boost the Primary Hepatocytes market.

Sep 28, 2021: Thermo Fisher Scientific launched the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit. This kit is designed to safely collect saliva for research.

What Can be Explored with the Primary Hepatocytes Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Primary Hepatocytes Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Primary Hepatocytes
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Primary Hepatocytes market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Primary Hepatocytes market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Government Agency, Suppliers, Healthcare Industry and Clinic Centres.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Primary Hepatocytes Market?
The Primary Hepatocytes market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Primary Hepatocytes Market?
Top performing companies in the Global Primary Hepatocytes market are Thermo Fisher Scientific, Inc. (United States), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (United States), PromoCell GmbH (Germany), HemaCare Corporation (United States), ZenBio, Inc. (United States), STEMCELL Technologies, Inc. (Canada), Axol Bioscience Ltd. (United Kingdom), iXCells Biotechnologies (United States), BioIVT (United States) and ScienCell Research Laboratories, Inc. (United States), to name a few.

3. What trending factors would impact Primary Hepatocytes Market growth most?
"Innovative cancer treatment methods" is seen as one of major influencing trends for Primary Hepatocytes Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Human Primary Cells
  • Animal Primary Cells

By End-Use Industry
  • Hospitals
  • Clinic Centre
  • Pharmaceuticals
  • Research institutes
  • Diagnostics laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Development of therapeutic antibodies for the treatment of diseases
      • 3.2.2. Rising demand for biotechnology and pharmaceutical industry
    • 3.3. Market Challenges
      • 3.3.1. An increasing number of diseases
    • 3.4. Market Trends
      • 3.4.1. Innovative cancer treatment methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Hepatocytes, by Type, End-Use Industry and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primary Hepatocytes (Value)
      • 5.2.1. Global Primary Hepatocytes by: Type (Value)
        • 5.2.1.1. Human Primary Cells
        • 5.2.1.2. Animal Primary Cells
      • 5.2.2. Global Primary Hepatocytes by: Type (Value)
        • 5.2.2.1. Human Primary Cells
        • 5.2.2.2. Animal Primary Cells
      • 5.2.3. Global Primary Hepatocytes by: End-Use Industry (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinic Centre
        • 5.2.3.3. Pharmaceuticals
        • 5.2.3.4. Research institutes
        • 5.2.3.5. Diagnostics laboratories
      • 5.2.4. Global Primary Hepatocytes Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Primary Hepatocytes (Price)
  • 6. Primary Hepatocytes: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cell Biologics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PromoCell GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. HemaCare Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ZenBio, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. STEMCELL Technologies, Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Axol Bioscience Ltd. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. IXCells Biotechnologies (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BioIVT (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. ScienCell Research Laboratories, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Primary Hepatocytes Sale, by Type, End-Use Industry and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primary Hepatocytes (Value)
      • 7.2.1. Global Primary Hepatocytes by: Type (Value)
        • 7.2.1.1. Human Primary Cells
        • 7.2.1.2. Animal Primary Cells
      • 7.2.2. Global Primary Hepatocytes by: Type (Value)
        • 7.2.2.1. Human Primary Cells
        • 7.2.2.2. Animal Primary Cells
      • 7.2.3. Global Primary Hepatocytes by: End-Use Industry (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinic Centre
        • 7.2.3.3. Pharmaceuticals
        • 7.2.3.4. Research institutes
        • 7.2.3.5. Diagnostics laboratories
      • 7.2.4. Global Primary Hepatocytes Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Primary Hepatocytes (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Hepatocytes: by Type(USD Million)
  • Table 2. Primary Hepatocytes Human Primary Cells , by Region USD Million (2015-2020)
  • Table 3. Primary Hepatocytes Animal Primary Cells , by Region USD Million (2015-2020)
  • Table 4. Primary Hepatocytes: by Type(USD Million)
  • Table 5. Primary Hepatocytes Human Primary Cells , by Region USD Million (2015-2020)
  • Table 6. Primary Hepatocytes Animal Primary Cells , by Region USD Million (2015-2020)
  • Table 7. Primary Hepatocytes: by End-Use Industry(USD Million)
  • Table 8. Primary Hepatocytes Hospitals , by Region USD Million (2015-2020)
  • Table 9. Primary Hepatocytes Clinic Centre , by Region USD Million (2015-2020)
  • Table 10. Primary Hepatocytes Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 11. Primary Hepatocytes Research institutes , by Region USD Million (2015-2020)
  • Table 12. Primary Hepatocytes Diagnostics laboratories , by Region USD Million (2015-2020)
  • Table 13. South America Primary Hepatocytes, by Country USD Million (2015-2020)
  • Table 14. South America Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 15. South America Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 16. Brazil Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 17. Brazil Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 18. Argentina Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 19. Argentina Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 20. Rest of South America Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 21. Rest of South America Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 22. Asia Pacific Primary Hepatocytes, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 24. Asia Pacific Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 25. China Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 26. China Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 27. Japan Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 28. Japan Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 29. India Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 30. India Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 31. South Korea Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 32. South Korea Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 33. Taiwan Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 34. Taiwan Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 35. Australia Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 36. Australia Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 38. Rest of Asia-Pacific Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 39. Europe Primary Hepatocytes, by Country USD Million (2015-2020)
  • Table 40. Europe Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 41. Europe Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 42. Germany Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 43. Germany Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 44. France Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 45. France Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 46. Italy Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 47. Italy Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 48. United Kingdom Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 49. United Kingdom Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 50. Netherlands Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 51. Netherlands Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 52. Rest of Europe Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 53. Rest of Europe Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 54. MEA Primary Hepatocytes, by Country USD Million (2015-2020)
  • Table 55. MEA Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 56. MEA Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 57. Middle East Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 58. Middle East Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 59. Africa Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 60. Africa Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 61. North America Primary Hepatocytes, by Country USD Million (2015-2020)
  • Table 62. North America Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 63. North America Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 64. United States Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 65. United States Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 66. Canada Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 67. Canada Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 68. Mexico Primary Hepatocytes, by Type USD Million (2015-2020)
  • Table 69. Mexico Primary Hepatocytes, by End-Use Industry USD Million (2015-2020)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Primary Hepatocytes: by Type(USD Million)
  • Table 83. Primary Hepatocytes Human Primary Cells , by Region USD Million (2021-2026)
  • Table 84. Primary Hepatocytes Animal Primary Cells , by Region USD Million (2021-2026)
  • Table 85. Primary Hepatocytes: by Type(USD Million)
  • Table 86. Primary Hepatocytes Human Primary Cells , by Region USD Million (2021-2026)
  • Table 87. Primary Hepatocytes Animal Primary Cells , by Region USD Million (2021-2026)
  • Table 88. Primary Hepatocytes: by End-Use Industry(USD Million)
  • Table 89. Primary Hepatocytes Hospitals , by Region USD Million (2021-2026)
  • Table 90. Primary Hepatocytes Clinic Centre , by Region USD Million (2021-2026)
  • Table 91. Primary Hepatocytes Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 92. Primary Hepatocytes Research institutes , by Region USD Million (2021-2026)
  • Table 93. Primary Hepatocytes Diagnostics laboratories , by Region USD Million (2021-2026)
  • Table 94. South America Primary Hepatocytes, by Country USD Million (2021-2026)
  • Table 95. South America Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 96. South America Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 97. Brazil Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 98. Brazil Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 99. Argentina Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 100. Argentina Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 101. Rest of South America Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 102. Rest of South America Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 103. Asia Pacific Primary Hepatocytes, by Country USD Million (2021-2026)
  • Table 104. Asia Pacific Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 105. Asia Pacific Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 106. China Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 107. China Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 108. Japan Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 109. Japan Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 110. India Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 111. India Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 112. South Korea Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 113. South Korea Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 114. Taiwan Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 115. Taiwan Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 116. Australia Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 117. Australia Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 118. Rest of Asia-Pacific Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 119. Rest of Asia-Pacific Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 120. Europe Primary Hepatocytes, by Country USD Million (2021-2026)
  • Table 121. Europe Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 122. Europe Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 123. Germany Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 124. Germany Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 125. France Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 126. France Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 127. Italy Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 128. Italy Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 129. United Kingdom Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 130. United Kingdom Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 131. Netherlands Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 132. Netherlands Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 133. Rest of Europe Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 134. Rest of Europe Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 135. MEA Primary Hepatocytes, by Country USD Million (2021-2026)
  • Table 136. MEA Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 137. MEA Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 138. Middle East Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 139. Middle East Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 140. Africa Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 141. Africa Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 142. North America Primary Hepatocytes, by Country USD Million (2021-2026)
  • Table 143. North America Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 144. North America Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 145. United States Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 146. United States Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 147. Canada Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 148. Canada Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 149. Mexico Primary Hepatocytes, by Type USD Million (2021-2026)
  • Table 150. Mexico Primary Hepatocytes, by End-Use Industry USD Million (2021-2026)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Hepatocytes: by Type USD Million (2015-2020)
  • Figure 5. Global Primary Hepatocytes: by Type USD Million (2015-2020)
  • Figure 6. Global Primary Hepatocytes: by End-Use Industry USD Million (2015-2020)
  • Figure 7. South America Primary Hepatocytes Share (%), by Country
  • Figure 8. Asia Pacific Primary Hepatocytes Share (%), by Country
  • Figure 9. Europe Primary Hepatocytes Share (%), by Country
  • Figure 10. MEA Primary Hepatocytes Share (%), by Country
  • Figure 11. North America Primary Hepatocytes Share (%), by Country
  • Figure 12. Global Primary Hepatocytes share by Players 2020 (%)
  • Figure 13. Global Primary Hepatocytes share by Players (Top 3) 2020(%)
  • Figure 14. Global Primary Hepatocytes share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 20. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 22. Cell Biologics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cell Biologics, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. PromoCell GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. PromoCell GmbH (Germany) Revenue: by Geography 2020
  • Figure 26. HemaCare Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. HemaCare Corporation (United States) Revenue: by Geography 2020
  • Figure 28. ZenBio, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. ZenBio, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. STEMCELL Technologies, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 31. STEMCELL Technologies, Inc. (Canada) Revenue: by Geography 2020
  • Figure 32. Axol Bioscience Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Axol Bioscience Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 34. IXCells Biotechnologies (United States) Revenue, Net Income and Gross profit
  • Figure 35. IXCells Biotechnologies (United States) Revenue: by Geography 2020
  • Figure 36. BioIVT (United States) Revenue, Net Income and Gross profit
  • Figure 37. BioIVT (United States) Revenue: by Geography 2020
  • Figure 38. ScienCell Research Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. ScienCell Research Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Global Primary Hepatocytes: by Type USD Million (2021-2026)
  • Figure 41. Global Primary Hepatocytes: by Type USD Million (2021-2026)
  • Figure 42. Global Primary Hepatocytes: by End-Use Industry USD Million (2021-2026)
  • Figure 43. South America Primary Hepatocytes Share (%), by Country
  • Figure 44. Asia Pacific Primary Hepatocytes Share (%), by Country
  • Figure 45. Europe Primary Hepatocytes Share (%), by Country
  • Figure 46. MEA Primary Hepatocytes Share (%), by Country
  • Figure 47. North America Primary Hepatocytes Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific, Inc. (United States)
  • Merck KGaA (Germany)
  • Lonza (Switzerland)
  • Cell Biologics, Inc. (United States)
  • PromoCell GmbH (Germany)
  • HemaCare Corporation (United States)
  • ZenBio, Inc. (United States)
  • STEMCELL Technologies, Inc. (Canada)
  • Axol Bioscience Ltd. (United Kingdom)
  • iXCells Biotechnologies (United States)
  • BioIVT (United States)
  • ScienCell Research Laboratories, Inc. (United States)
Additional players considered in the study are as follows:
BPS Bioscience, Inc. (California) , ReachBio LLC (United States) , Biopredic International (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation